Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 3/20 | 0.53 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.53 |
| ▸ | PPARA | Q07869 | 7/20 | 0.49 |
| ▸ | PPARG | P37231 | 5/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1881521 | 1.00 | LPL (0.53) | LPLLIPGPPARAPPARG | |
| SCHEMBL5147572 | 1.00 | LPL (0.53) | LPLLIPGPPARAPPARG | |
| SCHEMBL11440647 | 1.00 | LPL (0.53) | LPLLIPGPPARAPPARG | |
| SCHEMBL4083034 | 1.00 | LPL (0.53) | LPLLIPGPPARAPPARG | |
| SCHEMBL7292054 | 0.98 | LPL (0.51) | LPLLIPGPPARAPPARG | |
| SCHEMBL3032724 | 0.93 | HDAC4 (0.47) | LPLLIPGPPARAPPARG | |
| SCHEMBL9480031 | 0.86 | MAOA (0.51) | — | |
| SCHEMBL9559961 | 0.86 | MAOA (0.51) | — | |
| SCHEMBL910179 | 0.85 | MAOA (0.46) | — | |
| SCHEMBL677009 | 0.84 | LPL (0.54) | LPLLIPGPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023196527-A2 | IONIZABLE LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | SunVax mRNA Therapeutics Inc. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230322689-A1 | IONIZABLE LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | SunVax mRNA Therapeutics Inc. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322689-A1 | IONIZABLE LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | SunVax mRNA Therapeutics Inc. (US) | 2023-10-12 | — | — | US | disclosed |
| US-9688668-B2 | Long chain base sphingosine kinase inhibitors | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688668-B2 | Long chain base sphingosine kinase inhibitors | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688668-B2 | Long chain base sphingosine kinase inhibitors | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2017-06-27 | — | — | US | disclosed |
| US-20150210675-A1 | LONG CHAIN BASE SPHINGOSINE KINASE INHIBITORS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2015-07-30 | — | — | US | disclosed |
| US-20150210675-A1 | LONG CHAIN BASE SPHINGOSINE KINASE INHIBITORS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2015-07-30 | — | — | US | disclosed |
| US-20150210675-A1 | LONG CHAIN BASE SPHINGOSINE KINASE INHIBITORS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2015-07-30 | — | — | US | disclosed |
| EP-2822548-A1 | LONG CHAIN BASE SPHINGOSINE KINASE INHIBITORS | University Of Virginia Patent Foundation (US) | 2015-01-14 | — | — | EP | disclosed |
| WO-2013119946-A1 | LONG CHAIN BASE SPHINGOSINE KINASE INHIBITORS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2013-08-15 | — | — | WO | disclosed |
| WO-2013119946-A1 | LONG CHAIN BASE SPHINGOSINE KINASE INHIBITORS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2013-08-15 | — | — | WO | disclosed |
| EP-1200460-A1 | PSEUDOMYCIN N-ACYL SIDE-CHAIN ANALOGS | ELI LILLY AND COMPANY (US) | 2002-05-02 | — | — | EP | disclosed |
| WO-2001005814-A1 | PSEUDOMYCIN N-ACYL SIDE-CHAIN ANALOGS | ELI LILLY AND COMPANY (US) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210675-A1 | LONG CHAIN BASE SPHINGOSINE KINASE INHIBITORS | SPHK1, SPHK2, SGPL1 | LPL 311/4885LIPG 165/4885PPARA 3843/4885 |
| US-20230322689-A1 | IONIZABLE LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | PHOSPHO1, SGMS1, PLIN3 | LPL 169/4885LIPG 24/4885PPARA 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.